Ionpath Demonstrates Real-Time Spatial Phenotyping Using MIBI Spatial Proteomics Technology at Society for Cancer Immunotherapy Annual Meeting

MENLO PARK, CA–(BUSINESS WIRE)–Ionpath, a pioneer in high-resolution spatial proteomics, today announced that the results of several studies enabled by multiplexed ion beam imaging (MIBI™) technology will be presented in posters at the Society for Immunotherapy Annual Meeting at cancer this week (SITC). Ionpath will also present MIBIscope’s first-ever real-time spatial phenotyping data collection shared via live stream at the exhibit hall booth (#200). The new feature is part of a 24-hour sample-to-response workflow. A demonstration of the new AI-based part of the workflow will also be available at the booth.

Ionpath’s MIBI technology system provides real-world insights into individual cells in their complex tissue microenvironment with the throughput and reproducibility required for clinical research. The MIBI platform is based on highly multiplexed, quantitative protein imaging with unmatched sensitivity and true subcellular resolution. It allows researchers to visualize 40 proteins simultaneously, enabling deep phenotypic profiling and spatial analysis of the tumor microenvironment.

“In the oncology and immunotherapy communities, many scientists have already generated remarkable new results and insights into disease progression and treatment response with MIBI technology,” said Sander Gubbens, MD, CEO of Ionpath. “We are delighted that SITC conference attendees will have the opportunity to explore some of these results in poster presentations and see our platform in action at our conference booth to better understand how high-resolution spatial proteomics can support critical cancer research. ”

SITC 2022 Poster Presentations

Poster #89

“Multiplexed ion beam imaging (MIBI) reveals adaptive immune responses associated with clinical outcomes in neoadjuvant PD-1 inhibitor-treated oral squamous cell carcinoma”

Raghav Padmanabhan, Hannah M. Knochelmann, Monirath Hav, Mate L. Nagy, Peng Si, Sweta Bajaj, Gregory B. Lesinski, David Neskey, and Chrystal M. Paulos

Poster #1292

“A reproducible multiplex imaging (MIBI) data analysis pipeline with application to uncover novel features of the tumor-immune microenvironment”

Jessica Maxey, Marshall A. Thompson, Katie Campbell, Benjamin Kamphaus, Zaid Bustami, Sandra Santulli-Marotto, Daniel Wells, Silvia Boffo, Lisa M. Salvador, Philip O. Scompia, Christine N. Spencer, Adam Schoenfeld, Antony Ribas, and Lacey J. Kitsch

Poster #1294

“An Automated Machine Learning Framework for Rapid Quantification and Analysis of Multiplexed Ion Beam Imaging (MIBI)”

Raghav Padmanabhan, Mate L. Nagy, Stanislaw Nowak, Peng Si, Sweta Bajaj and Monirath Hav

Poster #1446

Multiplexed ion beam imaging identifies B-cell enrichment in the RHAMM-highly invasive breast cancer niche

Yu Yu He, Grant M. Bartel, Raghav Padmanabhan, Colleen Forster, Hannah Ruth, Mate L. Nagy, Stanislav Novak, James B. McCarthy, Kathryn L. Schwertfeger, and Andrew K. Nelson

About Ionpath

Ionpath, Inc., is a pioneer in high-resolution spatial proteomics, revolutionizing tissue imaging and analysis to accelerate medical discovery and improve human health. Ionpath’s MIBI™ (multiplexed ion beam imaging) platform overcomes the limitations of traditional immunohistochemistry, enabling a deeper understanding of the tissue microenvironment with highly multiplexed, quantitative single-cell analysis. With MIBI technology and the expertise of world-class pathology and data science teams, Ionpath provides actionable insights for translational and clinical researchers at leading pharmaceutical, biotechnology and research organizations in immuno-oncology, immunology, neuroscience and infectious disease research. For more information, visit www.ionpath.com.

Leave a Comment